证券之星消息，12月22日南向资金减持4.09万股讯飞医疗科技（02506.HK）。近5个交易日中，获南向 资金减持的有4天，累计净减持10.79万股。近20个交易日中，获南向资金增持的有14天，累计净增持 9.16万股。截至目前，南向资金持有讯飞医疗科技（02506.HK）397.86万股，占公司已发行普通股的 5.14%。 讯飞医疗科技股份有限公司是一家主要从事提供人工智能赋能的医疗解决方案的中国公司。基层医疗服 务业务线由智医助理及慢病管理组成。医院服务业务线包括智慧医院解决方案和诊疗助理。患者服务业 务线包括智慧医院患者服务与诊后管理（包括讯飞晓医App及小程序）、影像云平台以及医疗器械。区 域管理平台解决方案业务线包括智慧卫生解决方案和智慧医保。该公司主要在国内市场开展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

第八届"上海医改十大创新举措"评选提名奖包括：急诊多学科协同创新，筑牢危重急症患者生命防线； 构建中西医协同新范式，多措并举提升医疗服务质量；预防为主 关口前移——打造新时代妇幼健康"科 普大摇篮"等。 据介绍，自2017年起，上海在全国率先开展省级层面的十大医改创新举措评选，至今累计申报667项举 措。 ■ 全面实施二、三级医院门诊号源优先向基层开放，助力分级诊疗制度建设； ■ 助力多元支付，赋能商保发展，探索医保商保直赔"上海模式"； ■ 先行先试提升临床试验质效，赋能创新药研发上市； ■ 人工智能赋能互联网医院助力分级诊疗，提高医疗供给和患者就医体验； ■"防、治、管、康"综合施策，筑牢市民心理健康防线； ■ 数字赋能医药服务新生态——"15分钟社区生活圈"便民配药服务创新实践； ■ 以口腔专科医联体建设为抓手，实践优质高效协同延续的整合型分级诊疗服务； ■ 以新质专科（专病）为突破口，同向发力，集成推动区属公立医院"强腰"行动落地见效； ■ 数据明志，规范致远——智慧医保护航康复医疗高质发展； ■ 依托医疗统计数据赋能健康保险服务，满足百姓多元健康服务需求。 本报讯（记者 郜阳）昨天，第八届"上海医改 ...

Core Viewpoint - Southbound funds increased their holdings in iFlytek Medical Technology (02506.HK) by 650.0 shares on November 17, 2025, while experiencing a net reduction of 4,500.0 shares over the past five trading days [1][2]. Group 1: Southbound Fund Activity - In the last 20 trading days, iFlytek Medical Technology saw 12 days of net increases in southbound fund holdings, totaling 82,600 shares [1]. - As of November 17, 2025, southbound funds hold 3.7932 million shares of iFlytek Medical Technology, representing 4.9% of the company's total issued ordinary shares [1][2]. Group 2: Company Overview - iFlytek Medical Technology is primarily engaged in providing AI-powered medical solutions in China, with business lines including grassroots medical services, hospital services, patient services, and regional management platform solutions [2]. - The grassroots medical services line consists of intelligent medical assistants and chronic disease management, while the hospital services line includes smart hospital solutions and diagnostic assistance [2]. - Patient services encompass smart hospital patient services, post-discharge management, imaging cloud platforms, and medical devices [2].

Core Viewpoint - Southbound funds reduced their holdings in iFlytek Medical Technology (02506.HK) by 5,550 shares on October 16, 2025, indicating a slight decrease in investor confidence in the short term [1]. Group 1: Southbound Fund Activity - In the last five trading days, southbound funds increased their holdings on three days, with a total net increase of 85,400 shares [1]. - Over the past 20 trading days, there were 16 days of net increases, totaling 253,400 shares [1]. - As of now, southbound funds hold 3,710,600 shares of iFlytek Medical Technology, accounting for 4.79% of the company's total issued ordinary shares [1]. Group 2: Company Overview - iFlytek Medical Technology Co., Ltd. primarily provides AI-enabled medical solutions in China [2]. - The company's business lines include grassroots medical services (intelligent medical assistants and chronic disease management), hospital services (smart hospital solutions and diagnostic assistants), and patient services (smart hospital patient services and post-discharge management) [2]. - The regional management platform solutions include smart health solutions and smart medical insurance [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 最新業務進展 本公告乃由雲知聲智能科技股份有限公司（「本公司」）自願作出，旨在知會本公司股東 及潛在投資者有關本公司的最新業務發展情況。 UNISOUND AI TECHNOLOGY CO., LTD. 雲知聲智能科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9678） 自願性公告 於本公告日期，本公司董事會包括：(i)執行董事梁家恩博士、黃偉博士、康恒博士、李霄寒先生、劉升平先生及 李鵬先生；(ii)非執行董事鄺子平先生、李志超先生、汪存富先生及李昂先生；及(iii)獨立非執行董事胡建軍先生、 樊健先生、金慧華女士、張坤博士及陳華先生。 本公司董事會（「董事會」）欣然宣佈，本公司成功中標首都醫科大學北京友誼醫院（「北 京友誼醫院」）AI能力平台等多個智能體（Agent）項目，實現與北京友誼醫院在目前合作 基礎上服務關係的進一步深化，也標誌著本公司在智慧醫療領域的技術落地和商業 ...

Core Viewpoint - The company primarily operates in the domestic market, providing AI-enabled medical solutions, with business lines including primary healthcare services, hospital services, patient services, and regional management platform solutions [5] Revenue and Profit Growth - Historical revenue and net profit growth rates show fluctuations, with a notable increase in revenue growth rate in 2023 compared to previous years [7][10] - The company's revenue for the first half of 2025 is composed of various segments: hospital solutions (0.529 billion), patient management services (1.043 billion), regional solutions (0.576 billion), and primary healthcare solutions (0.838 billion) [9] Financial Performance Metrics - In the first half of 2025, the average return on equity was -8.2%, an increase of 20.62 percentage points from the same period last year [14] - The company's total asset turnover ratio has shown a consistent trend, with a notable value of 0.44 times in 2025H1 [17] Asset and Liability Changes - As of the first half of 2025, significant changes in assets include a 7.7% increase in receivables, a 44.97% increase in long-term receivables, a 28.7% increase in inventory, and a 77.75% increase in contract assets [23] - On the liabilities side, long-term borrowings increased by 224.07%, and short-term borrowings increased by 68.61%, indicating a rise in the proportion of total assets [26] Liquidity Ratios - The company reported a current ratio of 1.60 and a quick ratio of 1.49 in the first half of 2025, indicating a stable liquidity position [29]